Literature DB >> 2059970

Inhibition of mammary tumorigenesis in virgin rats by adoptive transfer of splenocytes from parous donors.

P K Chakravarty1, D K Sinha.   

Abstract

Splenocytes from parous rats have been previously found to have cytotoxic activity against mammary tumor cells in vitro. Experiments were carried out to determine if this pregnancy-induced cytotoxic nature of the splenocytes is inherent and transferable. Splenocytes from parous rats wer adoptively transferred to a group of virgin rats. Another group of age-matched, virgin rats received splenocytes from virgin donors in a similar way. After a period of rest, at the age of 55 days, the rats belonging to both of the groups, received 7,12-dimethylbenz(a)anthracene (DMBA) intragastrically. A third group of untreated virgin rats were also given the chemical carcinogen the same way as above and were considered as intact controls. The rats were monitored for development and growth of mammary tumor from 60 days of DMBA administration. After 4 months of DMBA administration the rats were sacrificed and mammary glands were examined for tumors. Mammary glands with no visible tumors were taken for whole mount preparation, to be examined for microscopic lesions. The results showed that 33 of 41 intact control rats, developed tumor and 27 of the 34 rats that received spleen cells from virgin rats developed tumors. Of the rats that received spleen cells from parous rats, only 18 out of 37 rats developed tumors, indicating an inhibition of tumor induction in these rats. Growth rate of the tumors in this group was also slower than in the control groups.

Entities:  

Mesh:

Year:  1991        PMID: 2059970     DOI: 10.1007/bf01744946

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

Review 1.  An analysis of the murine NK cell as to structure, function and biological relevance.

Authors:  R Kiessling; H Wigzell
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 2.  Natural cell-mediated immunity.

Authors:  R B Herberman; H T Holden
Journal:  Adv Cancer Res       Date:  1978       Impact factor: 6.242

Review 3.  Biological and molecular bases of mammary carcinogenesis.

Authors:  J Russo; I H Russo
Journal:  Lab Invest       Date:  1987-08       Impact factor: 5.662

4.  Immune response to a syngeneic mammary adenocarcinoma. III. Development of memory and suppressor functions modulating cellular cytotoxicity.

Authors:  O Kuperman; G W Fortner; Z J Lucas
Journal:  J Immunol       Date:  1975-11       Impact factor: 5.422

5.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer.

Authors:  L V Crawford; D C Pim; R D Bulbrook
Journal:  Int J Cancer       Date:  1982-10-15       Impact factor: 7.396

6.  Detection of placental protein five (PP5) and pregnancy-specific glycoprotein (SP1) in benign and malignant breast disease.

Authors:  R D Bremner; A D Nisbet; R Herriot; C H Horne; C McArdle; D Crawford; H Bohn
Journal:  Oncodev Biol Med       Date:  1981

7.  Pregnancy-induced cytotoxicity of splenocytes against mammary tumor cells in rats.

Authors:  P K Chakravarty; S K Ghosh; D K Sinha
Journal:  Oncology       Date:  1991       Impact factor: 2.935

8.  Lymphocytes that mediate systemic resistance to in vivo growth of a carcinogen-induced syngeneic tumor.

Authors:  E D Crum
Journal:  Int J Cancer       Date:  1980-07-15       Impact factor: 7.396

9.  Susceptibility of the mammary gland to carcinogenesis. II. Pregnancy interruption as a risk factor in tumor incidence.

Authors:  J Russo; I H Russo
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

10.  Prevention of mammary carcinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy.

Authors:  D K Sinha; J E Pazik; T L Dao
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

View more
  1 in total

1.  Parity improves anti-tumor immunity in breast cancer patients.

Authors:  Philipp Beckhove; Christoph Domschke; Anna-Lena Krause; Florian Schuetz; Marc Boudewijns; Maria Pritsch; Markus Wallwiener; Michael Golatta; Joachim Rom; Joerg Heil; Christof Sohn; Andreas Schneeweiss
Journal:  Oncotarget       Date:  2017-09-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.